Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 12319
Country/Region: Ethiopia
Year: 2016
Main Partner: Federal Police Commission - Ethiopia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $1,123,518 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $48,160
Care: TB/HIV (HVTB) $86,688
Care: Pediatric Care and Support (PDCS) $10,403
Laboratory Infrastructure (HLAB) $19,264
Strategic Information (HVSI) $40,443
Health Systems Strengthening (OHSS) $43,344
Testing: HIV Testing and Counseling (HVCT) $62,608
Sexual Prevention: Other Sexual Prevention (HVOP) $390,682
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $21,376
Treatment: Adult Treatment (HTXS) $387,788
Treatment: Pediatric Treatment (PDTX) $12,762
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 27
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 20
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 30
GEND_GBV Number of people receiving post-GBV care 2017 50
HRH_PRE By Graduates: Nurses 2017 55
HRH_PRE By Graduates: Other 2017 80
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2017 135
HRH_PRE Sum of Graduates disaggregates 2017 135
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 1,000
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 1,000
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 4,000
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 14,000
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 20,000
HTS_TST Service Delivery Point (Facility): Index testing 2017 1,000
HTS_TST Service Delivery Point (Facility): Inpatient 2017 1,000
HTS_TST Service Delivery Point (Facility): Other PITC 2017 6,966
HTS_TST Service Delivery Point (Facility): Outpatient 2017 2,000
HTS_TST Service Delivery Point (Facility): Pediatric 2017 2,000
HTS_TST Service Delivery Point (Facility): PMTCT 2017 1,434
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 600
HTS_TST Service Delivery Point (Facility): VCT 2017 5,000
HTS_TST Sum of Aggregated Age/Sex <15 2017 2,000
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 18,000
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 20,000
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 3
LAB_PT CD4: Number of laboratories that perform this testing 2017 3
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 5
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 5
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 5
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 3
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 5
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 1
PMTCT_ART Already on ART at beginning of current pregnancy 2017 28
PMTCT_ART New on ART 2017 15
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 1,464
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 31
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 8
PMTCT_EID Sum of Infant Age disaggregates 2017 39
PMTCT_STAT By: Known positives at entry 2017 30
PMTCT_STAT By: Number of new positives identified 2017 15
PMTCT_STAT Number of new ANC and L&D clients 2017 1,541
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 1,464
PMTCT_STAT Sum of Positives Status disaggregates 2017 45
PP_PREV Aggregated Age/sex: 15+ Female 2017 1,915
PP_PREV Aggregated Age/sex: 15+ Male 2017 20,890
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 22,805
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 11
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 45
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 56
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 56
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 1,782
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 764
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 534
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 713
TB_SCREENDX Screen Result: Screened Positive for TB 2017 255
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 885
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 1,544
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 53
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 63
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 2,545
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 6
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 46
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 6
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 171
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 224
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 229
TX_CURR Aggregated Age/Sex: <15 Female 2017 57
TX_CURR Aggregated Age/Sex: <15 Male 2017 69
TX_CURR Aggregated Age/Sex: 15+ Female 2017 985
TX_CURR Aggregated Age/Sex: 15+ Male 2017 1,717
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 2,828
TX_CURR Sum of Aggregated Age/Sex <15 2017 126
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 2,702
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 2,828
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 7
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 7
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 85
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 147
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 246
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 246
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 1,697
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 1,528
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 31
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 38
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 532
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 927
TX_PVLS Numerator: Indication: Routine 2017 1,527
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 34
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 42
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 591
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 1,030
TX_PVLS_den Denominator: Indication: Routine 2017 1,528
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 55
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 111
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 174
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 205
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 62
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 132
Cross Cutting Budget Categories and Known Amounts Total: $117,406
Gender: Gender Based Violence (GBV) $34,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Food and Nutrition: Policy, Tools, and Service Delivery $6,261
Human Resources for Health $43,344
Renovation $33,801